News

Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat masseter muscle prominence. If cleared, BOTOX Cosmetic would be the first neurotoxin approved in the U.S. for this condition, supported by positive Phase 3 trial data. The filing highlights AbbVie’s push to broaden its aesthetics offerings beyond current BOTOX Cosmetic indications. AbbVie (NYSE:ABBV) is drawing fresh attention to its...

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph

Your portfolio could be paying you quarterly income right now from three companies that have raised their dividends for decades straight, but the next ex-dates are approaching fast and missing them means waiting another quarter to collect.

AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ (upadacitinib) as the first systemic treatment in the EU for non segmental vitiligo. The decision also covers RINVOQ as a systemic option for severe alopecia areata in adults and adolescents. These approvals expand RINVOQ’s labeled uses in Europe and add new indications in dermatology and immunology. For investors following AbbVie, this move adds fresh detail to the story around its immunology franchise. The company...

AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.

Stocks rose in midday trading Friday, erasing earlier losses as investors assessed earnings from maj

Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates

Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.

Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.

AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.

AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.

AbbVie still looks like a compelling buy at its all-time high.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen AbbVie's immunology pipeline.

AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.

Both have very promising futures.

HDV quietly stacks a 3.1% income stream on top of equity gains that have left the S&P 500 in the dust this year, but the fund's concentrated sector bets carry a catch that most yield-seekers overlook.

It looks like a great buy-and-hold option.

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day.

Strong biotech returns, major pharma acquisitions and new IPO filings are reshaping the 2026 U.S. listing market.

They can help stabilize your portfolio in these otherwise volatile times.

Allergan Aesthetics, an AbbVie company (NYSE:ABBV), received European Commission approval for Boey (trenibotulinumtoxinE). Boey is described as the first rapid onset, short duration neurotoxin for the treatment of frown lines available in Europe. This approval gives AbbVie a differentiated addition to its aesthetics portfolio in Europe, an area where the company already has an established presence. By targeting frown lines with a rapid onset profile and shorter treatment duration, Boey is...

With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.

AbbVie, Enbridge, and Coca-Cola pay high dividends and are the types of stocks that investors can buy and forget about.

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.